Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor
cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
Combining vaccine therapy and interleukin-2 may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without
interleukin-2 in treating patients with metastatic melanoma that has not responded to
previous treatment.